August 20th, 2026
Researchers here review the present state of research and use of metformin as a geroprotective drug, intended to modestly slow aging. They are largely on point, if somewhat too accepting of the quality of the existing human data. While effective as a treatment for metabolic syndrome and type 2 diabetes, metformin is nowhere near as good a choice as rapamycin if forced to pick a geroprotective drug with modest effects on aging. For one, the animal data for effects on aging is very mixed, and there are sizeable methodological and other concerns regarding the human clinical trial evidence for reduced mortality and increased life expectancy. More recent human data tends to show little to no effect on that front.
Metformin is a biguanide and first line drug for type 2 diabetes (T2D) mellitus that is being recognized as a geroprotective agent capable of influencing important hallmarks of aging. Apart from its primary role in lowering blood glucose levels, metformin has been shown to have several effects at the molecular level. It acts by activating the AMPK, which leads to a cascade of downstream events such as the inhibition of mTOR, increased mitochondrial biogenesis, and autophagy, as well as epigenetic modifications. Current findings also showed its capacity to alter the gut microbiota by increasing short-chain fatty acid producing bacteria, indicating the involvement of other systemic pathways that aid in lowering inflammation, increasing metabolic fitness, and keeping epigenetic stability.
